<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01171729</url>
  </required_header>
  <id_info>
    <org_study_id>2006-10-030</org_study_id>
    <nct_id>NCT01171729</nct_id>
  </id_info>
  <brief_title>Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer</brief_title>
  <official_title>A Phase I/IIa Study of Autologous Cell-based Vaccine Therapy With CreaVax-PC in Hormone-Refractory Metastatic Prostate Cancer Patients With PSA Relapse to Evaluate the Safety and Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, Phase I/IIa trial of immunotherapy with CreaVax-PC as treatment in men&#xD;
      with hormone-Refractory Metastatic Prostate Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CreaVax-PC consisted of antigen (PSA, PAP and KLH) primed dendritic cell is an&#xD;
      investigational product designed to activate a man's immune response, so they can detect&#xD;
      prostate cancer cells and initiate an immune response against prostate cancer antigens.&#xD;
&#xD;
      If patients decide to participate and are eligible, they will be enrolled in the study and&#xD;
      will receive active product (CreaVax-PC). In detail, patients will receive CreaVax-PC&#xD;
      injection at intervals of 3 weeks, maximum 6 times during 21 weeks. PSA increase rate is a&#xD;
      primary evaluation variables and tumor suppression effect is secondary evaluation variables.&#xD;
      We also evaluate time to progression, overall survival and immune response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA increment and absolute PSA response</measure>
    <time_frame>12 weeks</time_frame>
    <description>PSA response evaluation at 12 weeks and follow up response evaluation at 21 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>DC Injection to time to progression or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Patients will be followed until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response(DTH response, Interferon-gamma Elispot assay, proliferation assay, ELISA)</measure>
    <time_frame>weeks 0, 12, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>week 0, 12, 21</time_frame>
    <description>Clinical course of participants as measured by bone scans and CT</description>
  </secondary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Prostatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous dendritic cell</intervention_name>
    <description>Autologous dendritic cells pulsed with prostate cancer antigen and KLH</description>
    <other_name>CreaVax-PC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Histological confirmed prostatic carcinoma patient&#xD;
&#xD;
          -  2) Hormone non-respondence ex1) Although treatment PSA ≥ 5ng/ml ex2) PSA level were&#xD;
             measured two times ex3) Prior one year radiology were processed&#xD;
&#xD;
          -  3) Just 18 years over&#xD;
&#xD;
          -  4) Has a score ≤1 on the ECOG Performance Scale&#xD;
&#xD;
          -  5) Expected survival life time ≥ 6month&#xD;
&#xD;
          -  6) Adequate bone marrow function hemoglobin ≥ 10.0g/dL , leukocyte count ≥ 4,000/mm3&#xD;
             thrombocyte ≥ 100,000/mm3&#xD;
&#xD;
          -  7) Adequate blood coagulation function PT(INR) &lt; 1.5, aPTT&lt; 1.5 x control&#xD;
&#xD;
          -  8) Adequate kidney function Normal blood upper level Creatinine ≤ 1.5 times&#xD;
&#xD;
          -  9) Adequate liver function Normal blood upper level AST/ALT ≤ 1.5 times&#xD;
&#xD;
          -  10) Autoimmune antibody system don't have disorder ex) anti-nuclear antibody,&#xD;
             anti-thyroglobulin antibody negativity&#xD;
&#xD;
          -  11) Person who didn't treat prior 6 weeks operation, radiotherapy&#xD;
             treatment,immunotherapy or chemotherapy&#xD;
&#xD;
          -  12) Patient who voluntarily participated clinical trial and confirmed a written&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1) Having other malignancy or previous history of malignancy&#xD;
&#xD;
          -  2) Brain metastases patient&#xD;
&#xD;
          -  3) Having autoimmune disease or its history&#xD;
&#xD;
          -  4) Pyrexia, rigor, leukocytosis infectious disease&#xD;
&#xD;
          -  5) HBsAg, anti-HCV, HIV positive patient&#xD;
&#xD;
          -  6) Myocardial infarction, cardiac insufficiency, other severe heart disease and&#xD;
             non-controlled hypertension&#xD;
&#xD;
          -  7) Severe and active medical disease&#xD;
&#xD;
          -  8) Mental history disease or epilepsy&#xD;
&#xD;
          -  9) Patients participated other clinical trial within 4 weeks&#xD;
&#xD;
          -  10) Patients impossible to participate this trial by investigator's decision&#xD;
&#xD;
          -  11) Patients who received immunosuppressant such as steroid, cyclosporin A,&#xD;
             azathioprine within 6 weeks&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J C W, M.D,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>323 Ilsan-ro Ilsandong-gu Goyang-si</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-Gu, Ilwon-Dong</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>July 27, 2010</study_first_submitted>
  <study_first_submitted_qc>July 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2010</study_first_posted>
  <last_update_submitted>August 10, 2010</last_update_submitted>
  <last_update_submitted_qc>August 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chul Won Jung, MD</name_title>
    <organization>Samsung Medical Center</organization>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>PSA</keyword>
  <keyword>Hormone refractory prostatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

